Celgene Inc., together with Health Canada, has warned Canadian healthcare providers of important information related REVLIMID® (lenalidomide) capsules. REVLIMID® has been authorized by health Canada for the treatment of deletion 5q myelodysplastic syndrome (del 5q MDS) who receive blood transfusions for anemia. REVLIMID® is also authorized for use with dexamethasone to treat patients with multiple myeloma (cancer of plasma cells) who have already had other, unsuccessful treatment.
The new product label as decided on between Celgene Inc. and Health Canada is being expanded to include the following information:
- Second cancers such as skin cancers or other invasive solid tumors have been reported in a small number of patients with multiple myeloma.
- These cases have been reported in patients while taking REVLIMID® or after treatment with REVLIMID® is completed.
REVLIMID has only given to a small number of patients.
Source – Health Canada